Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 3Gastrointestinal 2Sarcoma 1Head & Neck 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 36Head and Neck Neoplasms 19Oropharyngeal Neoplasms 7Recurrence 6Melanoma 6Prostatic Neoplasms 5Carcinoma, Squamous Cell 5Small Cell Lung Carcinoma 4Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Triple Negative Breast Neoplasms 3Thyroid Neoplasms 3Ovarian Neoplasms 3Neoplasms 3Mouth Neoplasms 3Esophageal Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Merkel Cell 3Carcinoma, Hepatocellular 3Stomach Neoplasms 2Sarcoma 2Nasopharyngeal Carcinoma 2Lung Neoplasms 2Laryngeal Neoplasms 2Laryngeal Diseases 2Esophageal Squamous Cell Carcinoma 2Turcot syndrome 1

Interventions

trametinib 3dabrafenib 3binimetinib 2Nivolumab 2Magnetic Resonance Spectroscopy 2Docetaxel 2Cisplatin 2ulixertinib 1trastuzumab biosimilar HLX02 1tipifarnib 1sapanisertib 1romidepsin 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1entrectinib 1entinostat 1durvalumab 1defactinib 1copanlisib 1cobimetinib 1capivasertib 1cabiralizumab 1adavosertib 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × durvalumab × Head & Neck × Clear all
NCT04521686 2026-04-22

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Eli Lilly and Company

Phase 1 Active not recruiting
200 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Breast Neoplasms, Chondrosarcoma, Colonic Neoplasms, Glioblastoma, Glioma, Melanoma, Prostatic Neoplasms, Thyroid Neoplasms, Central Nervous System Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡